ADIL Adial Pharmaceuticals Inc

0  0%
Previous Close 1.87
Price To Book 1.63
Market Cap 19,110,723
Shares 10,219,638
Volume 0
Short Ratio
Av. Daily Volume 85,971

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due in 2020. Data from second Phase 3 trial for U.S. required endpoint due 2022.
Alcohol use disorder

Latest News

  1. Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare
  2. Adial Pharmaceuticals Receives Notification Prior to Acceptance of Israeli Patent for AD04 in Alcohol Use Disorder
  3. Adial Pharmaceuticals and Tedor Pharma Announce Collaboration to Manufacture AD04 Through Commercialization
  4. Adial Pharmaceuticals Announces Collaboration Agreement with Eurofins for Genetic Biomarker Testing to Support Upcoming Phase 3 Clinical Trial for Alcohol Use Disorder
  5. Adial Pharmaceuticals CEO to Present at the ThinkEquity Conference on May 2nd in New York City
  6. Have Insiders Been Buying Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Shares This Year?
  7. Adial Pharmaceutical's Chief Medical Officer Dr. Bankole Johnson Featured on NBC West Palm Beach, Florida Affiliate
  8. Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy
  9. Bankole A. Johnson, M.D., Chief Medical Officer of Adial Pharmaceuticals Delivers Keynote Lecture; Receives Prestigious American Society of Addiction Medicine Award
  10. Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D.
  11. Adial Pharmaceuticals Announces Appointment of Bankole Johnson, M.D., as Chief Medical Officer
  12. Adial Pharmaceuticals Announces Filing to Update the Prior Registration Statement Registering the Shares Underlying the ADILW Warrants
  13. Adial CEO: A Medical Solution For Alcoholism Could Be Just Around The Corner
  14. Adial Pharmaceuticals Featured on CBS in San Francisco
  15. Adial Pharmaceuticals Announces Closing of $9.2 Million Underwritten Public Offering and Exercise of Underwriters’ Over-Allotment Option
  16. Four Biotech Stocks Setting The Standard On Thursday (2/21/19)
  17. Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
  18. Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial’s AD04 for its Phase 3 Trial
  19. Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse
  20. Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder